Article Text

Download PDFPDF
The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year
  1. A Kavanaugh1,
  2. C E Antoni2,
  3. D Gladman3,
  4. S Wassenberg4,
  5. B Zhou5,
  6. A Beutler5,
  7. G Keenan5,
  8. G Burmester6,
  9. D E Furst7,
  10. M H Weisman8,
  11. J R Kalden2,
  12. J Smolen9,
  13. D van der Heijde10,
  14. the IMPACT Study Group
  1. 1Center for Innovative Therapy, UCSD, San Diego, CA, USA
  2. 2Fredrich-Alexander-University, Erlangen, Germany
  3. 3University of Toronto, Toronto, ON, Canada
  4. 4Evangelisches Fachkrankenhaus, Ratingen, Germany
  5. 5Centocor, Inc., Malvern, PA, USA
  6. 6Charité Humboldt University, Berlin, Germany
  7. 7Virginia Mason Hospital, Seattle, WA, USA
  8. 8Cedar Sinai Hospital, Los Angeles, CA, USA
  9. 9Medical University of Vienna and Lainz Hospital, Vienna, Austria
  10. 10University Hospital Maastricht, Maastricht, the Netherlands
  1. Correspondence to:
    Dr Arthur Kavanaugh
    Center for Innovative Therapy, UCSD, 9500 Gilman Drive, La Jolla, CA 92093-0943, USA; akavanaugh{at}


Objective: Infliximab is effective in improving signs and symptoms of joint/skin involvement, functional status, and quality of life in patients with psoriatic arthritis (PsA). Using IMPACT trial data, we assessed the effect of infliximab (IFX) on structural damage in PsA.

Methods: Patients with active PsA were randomly assigned to receive placebo (PBO/IFX) or infliximab 5 mg/kg (IFX/IFX) at weeks 0, 2, 6, and 14, with the primary endpoint at week 16. The PBO group received infliximab loading doses at weeks 16, 18, and 22. Thereafter, all patients received infliximab 5 mg/kg every 8 weeks through week 50. Hand/feet radiographs were obtained at weeks 0 and 50. Total radiographic scores were determined using the PsA modified van der Heijde-Sharp (vdH-S) score. Projected annual rate of progression was calculated by dividing x ray score by disease duration (years).

Results: As reported previously, 65% of infliximab treated patients versus 10% of PBO treated patients achieved an ACR20 response at week 16 (p<0.001). At week 50, 69% of patients achieved an ACR20 response. Radiographs (baseline and week 50) were available for 72/104 patients. At baseline, estimated mean annual rate of progression was 5.8 modified vdH-S points/year. Mean (median) changes from baseline to week 50 in the total modified vdH-S score were −1.95 (−0.50) for PBO/IFX and −1.52 (−0.50) for IFX/IFX patients (p = NS). At week 50, 85% and 84% of patients in the PBO/IFX and IFX/IFX groups had no worsening in the total modified vdH-S score.

Conclusion: Infliximab inhibits radiographic progression in patients with PsA through week 50.

  • CRP, C-reactive protein
  • DIP, distal interphalangeal
  • DMARD, disease modifying antirheumatic drug
  • ESR, erythrocyte sedimentation rate
  • IFX, infliximab
  • IMPACT, Infliximab Multinational Psoriatic Arthritis Controlled Trial
  • JSN, joint space narrowing
  • MTX, methotrexate
  • PBO, placebo
  • PsA, psoriatic arthritis
  • RA, rheumatoid arthritis
  • SDD, smallest detectable difference
  • TNFα, tumour necrosis factor alpha
  • vdH-S score, van der Heijde-Sharp score
  • infliximab
  • psoriasis
  • psoriatic arthritis
  • structural damage
  • tumour necrosis factor α

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Published Online First 26 January 2006

  • This study was partially funded by Schering-Plough, Kenilworth, NJ, USA

  • Competing interests: Dr Kavanaugh has conducted research and training for Centocor for which he has been compensated. Dr Antoni has received consulting fess of less than $10 000 from Centocor and Schering-Plough and is currently an employee of Schering-Plough. Dr Gladman has received consulting fees from Centocor. Dr Furst has received research funds from Centocor. Dr Weisman has received consulting fees and research support from Centocor. Professor Smolen has received speaking fees from Centocor, Schering-Plough, Abbott, and Wyeth; research funds from Centocor; and consulting fees from Centocor, Schering-Plough, Abbott, and Wyeth. Professor van der Heijde has received speaking and consulting fees and research funds from Centocor. Professor Burmester has received funds from Centocor for conducting clinical research and serving as a consultant. Ms Zhou and Drs Beutler and G Keenan are employees of Centocor.